title: [The pharmacology of the lipoxygenase inhibitors oxphaman (1-(2,5-dihydroxybenzylidene)aminoadamantane) and oxphalin (1-(3,4-dihydroxybenzylidene)-2,4,6-trimethylaniline].
abstract: Oxphaman and particularly oxphalin, among other phenolic azomethines, have been proven as strong inhibitors of lipoxygenases (LOX) from reticulocytes, soybean, thrombocytes as well as of quasi-LOX (hemoglobin) with IC50 values which correspond with those of known LOX inhibitors. The 5-LOX is likewise strongly, the cyclooxygenase of sheep seminal vesicles only weakly inhibited. Nevertheless, antiinflammatory effectivity was found in some carrageenin-induced inflammatory models of the rat as well as in the arachidonic acid- and croton oil-induced ear oedema of the mouse. Adjuvant arthritis, experimental pain, skin permeability and allergy models (anaphylactic paw oedema, cutaneous anaphylaxis, asthma, picryl chloride ear oedema) were not, only weakly or irregularly influenced. In the guinea pig ileum a certain antihistaminic, anticholinergic and leukotriene antagonistic activity was found. An inflammation-induced vasodepression (anaphylactic shock, dextran paw oedema. UV irradiation) was dose-dependently prevented or even reversed, obviously on the basis of oxygen radical scavenging.
authors.affiliation: Martin Luther-Universität Halle-Wittenberg, Sektion Pharmazie, Wissenschaftsbereich Pharmakologie.
authors.forename: H
authors.initials: H
authors.lastname: Bekemeier
authors.forename: R
authors.initials: R
authors.lastname: Hirschelmann
authors.forename: A
authors.initials: A
authors.lastname: Langner
authors.forename: A J
authors.initials: AJ
authors.lastname: Giessler
authors.forename: E
authors.initials: E
authors.lastname: Krause
authors.forename: T
authors.initials: T
authors.lastname: Funke
authors.forename: F
authors.initials: F
authors.lastname: Hänsel
authors.forename: K
authors.initials: K
authors.lastname: Schmidt
authors.forename: S
authors.initials: S
authors.lastname: Zarnack
authors.forename: H H
authors.initials: HH
authors.lastname: Schumann
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000503:physiopathology; D001249:Asthma / Q000188:drug therapy; D001593:Benzyl Compounds / Q000494:pharmacology*; D004487:Edema / Q000188:drug therapy; D005609:Free Radicals; D006168:Guinea Pigs; D006633:Histamine Antagonists; D066298:In Vitro Techniques; D016859:Lipoxygenase Inhibitors; D008297:Male; D051379:Mice; D012156:Reticulocytes / Q000201:enzymology; D012869:Skin Absorption / Q000187:drug effects; D013025:Glycine max / Q000201:enzymology
chemical_list: D000814:Aniline Compounds; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001593:Benzyl Compounds; D005609:Free Radicals; D006633:Histamine Antagonists; D016859:Lipoxygenase Inhibitors; C061911:oxphaman; C061912:oxphalin; D000218:Adamantane
vernacular_title: Zur Pharmakologie der Lipoxygenasehemmer Oxphaman, 1-(2,5-Dihydroxybenzyliden)aminoadamanten, und Oxphalin, 1-(3,4-Dihydroxybenzyliden)-2,4,6-trimethylanilin.